These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 9330956)

  • 1. Chloroquine and cytokines.
    Wallace DJ
    J Rheumatol; 1997 Oct; 24(10):2051-2. PubMed ID: 9330956
    [No Abstract]   [Full Text] [Related]  

  • 2. [Disseminated lupus erythematosus. The continued efficacy of hydroxychloroquine scientifically proven by default].
    Carette S
    Union Med Can; 1991; 120(5):360-4. PubMed ID: 1962386
    [No Abstract]   [Full Text] [Related]  

  • 3. [Crug formulation and liberation of the active ingredient in of chloroquine phosphate].
    Gyarmati L; Stampf G; Morzsányi E; Soós G; Nagy E; Ablonczy E
    Acta Pharm Hung; 1975 Jul; 45(4):155-9. PubMed ID: 1096532
    [No Abstract]   [Full Text] [Related]  

  • 4. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity.
    Illei GG; Tackey E; Lapteva L; Lipsky PE
    Arthritis Rheum; 2004 Jul; 50(7):2048-65. PubMed ID: 15248202
    [No Abstract]   [Full Text] [Related]  

  • 5. Hydroxychloroquine in systemic lupus erythematosus.
    Disla E; Brar H; Taranta A
    N Engl J Med; 1991 Oct; 325(14):1046. PubMed ID: 1886629
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydroxychloroquine-induced pigmentation in two patients with systemic lupus erythematosus.
    Reynaert S; Setterfield J; Black MM
    J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):487-8. PubMed ID: 16643169
    [No Abstract]   [Full Text] [Related]  

  • 7. The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine.
    Namazi MR
    Lupus; 2009 Feb; 18(2):104-5. PubMed ID: 19151110
    [No Abstract]   [Full Text] [Related]  

  • 8. Hydroxychloroquine blood assay as a marker of nonadherence in patients with systemic lupus erythematosus: comment on the article by Koneru et al.
    Costedoat-Chalumeau N; Amoura Z; Marra D; Piette JC
    Arthritis Rheum; 2008 Jan; 59(1):153; author reply 153-4. PubMed ID: 18163410
    [No Abstract]   [Full Text] [Related]  

  • 9. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
    Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E
    Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapy for systemic lupus erythematosus.
    Lockshin MD
    N Engl J Med; 1991 Jan; 324(3):189-91. PubMed ID: 1984196
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction.
    Keating RJ; Bhatia S; Amin S; Williams A; Sinak LJ; Edwards WD
    J Am Soc Echocardiogr; 2005 Sep; 18(9):981. PubMed ID: 16153529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine reduces IL-6 and pro-thrombotic status.
    Sciascia S; Schreiber K; Radin M; Roccatello D; Krämer BK; Stach K
    Autoimmun Rev; 2020 Jul; 19(7):102555. PubMed ID: 32413408
    [No Abstract]   [Full Text] [Related]  

  • 13. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
    Costedoat-Chalumeau N; Amoura Z; Hulot JS; Hammoud HA; Aymard G; Cacoub P; Francès C; Wechsler B; Huong du LT; Ghillani P; Musset L; Lechat P; Piette JC
    Arthritis Rheum; 2006 Oct; 54(10):3284-90. PubMed ID: 17009263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early hydroxychloroquine macular toxicity.
    Warner AE
    Arthritis Rheum; 2001 Aug; 44(8):1959-61. PubMed ID: 11508449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Eye toxicity of antimalarial agents].
    Graña Gil J; Cabana Vázquez M; Vázquez González A; Sánchez Meizoso MO
    An Med Interna; 2002 Apr; 19(4):189-91. PubMed ID: 12090061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine myopathy.
    Richards AJ
    J Rheumatol; 1998 Aug; 25(8):1642-3. PubMed ID: 9712114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
    Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
    Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Blepharitis--rare in systemic lupus erythematosus].
    Gyl F; Anna-Adrien C; Oanţă A; Irimie M; Edit FJ
    Oftalmologia; 2008; 52(2):81-3. PubMed ID: 19065920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of hydroxychloroquine as an antirheumatic drug.
    Fox RI
    Semin Arthritis Rheum; 1993 Oct; 23(2 Suppl 1):82-91. PubMed ID: 8278823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs.
    Rahman P; Gladman DD; Urowitz MB; Yuen K; Hallett D; Bruce IN
    J Rheumatol; 1999 Feb; 26(2):325-30. PubMed ID: 9972966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.